Harrow Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Harrow Health, Inc. (formerly Imprimis Pharmaceuticals, Inc.) on May 16, 2019, reporting the conclusion of a federal jury trial regarding a lawsuit filed by Allergan USA, Inc. in September 2017. The lawsuit alleged violations of the federal Lanham Act and California's Sherman Act.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the specific legal damages awarded in the concluded trial.
Material Changes and Legal Outcome
On May 15, 2019, Allergan requested damages of $7,200,000 in lost profits and up to $54,000,000 in profit disgorgement. On May 16, 2019, the jury concluded the trial with the following findings:
- Lost Profit Damages: The Company was found liable for $48,500.
- Disgorged Profits: The Company was found liable for $0.00.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks beyond the specific litigation event. The primary contingency addressed was the potential liability from the Allergan lawsuit, which has now been resolved with a judgment significantly lower than the plaintiff's request.
Investor Verification Checklist
- Verify the finality of the $48,500 judgment and whether Allergan has filed any motions for reconsideration or appeal.
- Confirm if the $48,500 liability has been paid or if it is currently being contested.
- Review the Company's most recent 10-K or 10-Q to assess the impact of this liability on overall financial health, as this 8-K does not provide broader financial context.
- Check for any other pending litigation that may not be disclosed in this specific filing.